Retinal Physician – SUBSPECIALTY NEWS: Results in suprachoroidal trial, RNA therapy for RP, Beovu in DME, and more.
Results in suprachoroidal trial, RNA therapy for RP, Beovu in DME, and more.
Related Articles
May
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
New Product Applications
Harrow’s Iheezo, a topical ocular anesthetic, is the first FDA-approved use of chloroprocaine hydrochloride in the US ophthalmic market.
Coding Q&A
Retinal physicians face increasing pressure from government regulators and payors on various issues. To avoid regulatory scrutiny, it’s vital for practice administrators and owners to…
Upfront
Studies have shown upregulation of other VEGF subtypes when VEGF-A is blocked. This has led to several companies targeting VEGF-C and VEGF-D to improve outcomes…
Glaucoma Research Foundation Awards $2.5 Million in Grants
“This is the largest annual research budget in our 46-year history,” said Thomas M. Brunner, GRF President and CEO, in a news release.
Clinical Trial Update
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
Gene Therapy for Wet Age-related Macular Degeneration
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
Broader VEGF Pathway Inhibition for Wet AMD
VEGF-C and VEGF-D are innately involved in the neovascular etiology, so treating that component, in addition to traditional anti-VEGF-A treatment, may have the potential for…
Retinal Physician and the Entire Retina Community Mourn the Passing of Dr. Ramin Tadayoni
Dr. Tadayoni was well known internationally for his leadership in retinal surgery and ophthalmic education, and he was a revered mentor and friend.